Everolimus and Lutathera for refractory meningioma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs (everolimus and 177Lu-DOTATATE) for people with grade 2 or 3 meningioma that has grown despite prior treatments. It aims to see if this combination can slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 79 years old
- Your meningioma must be grade 2 or 3 and has grown or caused symptoms despite prior surgery or radiation
- A recent PET scan must show your tumor expresses somatostatin receptors (a protein that helps the drug target the tumor)
- You must have had a brain MRI and a specific PET scan (68Ga-DOTATOC) within the last 2 months
- You cannot be pregnant or breastfeeding and must use effective birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
This trial tests a type of radiation (protons) for brain tumors called atypical or anaplastic meningiomas that need radiotherapy. It may help by aiming radiation more precisely while also learning the safest and most effective dose.
This Phase 1 trial studies whether combining two targeted medicines—alpelisib and trametinib—can shrink or slow progressive meningiomas that have already been treated with standard surgery and radiation. If you qualify, you may help test a new treatment approach for tumors that keep growing.
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.